

IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS¹

PREAMBLE

1. BACKGROUND

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme to evaluate the carcinogenic risk of chemicals to humans and to produce monographs on individual chemicals. The *Monographs* programme has since been expanded to include consideration of exposures to complex mixtures of chemicals (which occur, for example, in some occupations and as a result of human habits) and of exposures to other agents, such as radiation and viruses. With Supplement 6, the title of the series was modified from *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans* to *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, in order to reflect the widened scope of the programme.

The criteria established in 1971 to evaluate carcinogenic risk to humans were adopted by the working groups whose deliberations resulted in the first 16 volumes of the *IARC Monographs* series. Those criteria were subsequently re-evaluated by working groups which met in 1977(1), 1978(2), 1979(3), 1982(4) and 1983(5). The present preamble was prepared by a Working Group which met in September 1986.

2. OBJECTIVE AND SCOPE

The objective of the programme is to prepare, with the help of international working groups of experts, and to publish in the form of monographs, critical reviews and evaluations of evidence on the carcinogenicity of a wide range of agents to which humans are or may be exposed. The *Monographs* may also indicate where additional research efforts are needed.

¹This project is supported by PHS Grant No. 5 UO1 CA33193-05 awarded by the US National Cancer Institute, Department of Health and Human Services, and with a subcontract to Tracor Jitco, Inc. and Technical Resources, Inc. Since 1986, this programme has also been supported by the Commission of the European Communities.

The *Monographs* represent the first step in carcinogenic risk assessment, which involves examination of all relevant information in order to assess the strength of the available evidence that, under certain conditions of exposure, an agent could alter the incidence of cancer in humans. The second step is quantitative risk estimation, which is not usually attempted in the *Monographs*. Detailed, quantitative evaluations of epidemiological data may be made in the *Monographs*, but without extrapolation beyond the range of the data available. Quantitative extrapolation from experimental data to the human situation is not undertaken.

These monographs may assist national and international authorities in making risk assessments and in formulating decisions concerning any necessary preventive measures. **No recommendation is given for regulation or legislation, since such decisions are made by individual governments and/or other international agencies.** The *IARC Monographs* are recognized as an authoritative source of information on the carcinogenicity of chemicals and complex exposures. A users' survey, made in 1984, indicated that the *Monographs* are consulted by various agencies in 45 countries. Each volume is printed in 4000 copies for distribution to governments, regulatory bodies and interested scientists. The *Monographs* are also available *via* the Distribution and Sales Service of the World Health Organization.

3. SELECTION OF TOPICS FOR MONOGRAPHS

Topics are selected on the basis of two main criteria: (a) that they concern agents for which there is evidence of human exposure, and (b) there is some evidence or suspicion of carcinogenicity. The term agent is used to include individual chemical compounds, groups of chemical compounds, physical agents (such as radiation), biological factors (such as viruses) and mixtures of agents such as occur in occupational exposures and as a result of personal and cultural habits (like smoking and dietary practices). Chemical analogues and compounds with biological or physical characteristics similar to those of suspected carcinogens may also be considered, even in the absence of data on carcinogenicity.

The scientific literature is surveyed for published data relevant to an assessment of carcinogenicity; the IARC surveys of chemicals being tested for carcinogenicity(6) and directories of on-going research in cancer epidemiology(7) often indicate those agents that may be scheduled for future meetings. An ad-hoc working group convened by IARC in 1984 gave recommendations as to which chemicals and exposures to complex mixtures should be evaluated in the *IARC Monographs* series(8).

As significant new data on subjects on which monographs have already been prepared become available, re-evaluations are made at subsequent meetings, and revised monographs are published.

4. DATA FOR MONOGRAPHS

The *Monographs* do not necessarily cite all of the literature on a particular agent. Only those data considered by the Working Group to be relevant to making an evaluation are included.

With regard to biological and epidemiological data, only reports that have been published or accepted for publication in the openly available scientific literature are reviewed by the working groups. In certain instances, government agency reports that have undergone peer review and are widely available are considered. Exceptions may be made on an ad-hoc basis to include unpublished reports that are in their final form and publicly available, if their inclusion is considered pertinent to making a final evaluation (see p. 29 *et seq.*). In the sections on chemical and physical properties and on production, use, occurrence and analysis, unpublished sources of information may be used.

5. THE WORKING GROUP

Reviews and evaluations are formulated by a working group of experts. The tasks of this group are five-fold: (i) to ascertain that all appropriate data have been collected; (ii) to select the data relevant for the evaluation on the basis of scientific merit; (iii) to prepare accurate summaries of the data to enable the reader to follow the reasoning of the Working Group; (iv) to evaluate the results of experimental and epidemiological studies; and (v) to make an overall evaluation of the carcinogenicity of the agent to humans.

Working Group participants who contributed to the consideration and evaluation of the agents within a particular volume are listed, with their addresses, at the beginning of each publication. Each participant who is a member of a working group serves as an individual scientist and not as a representative of any organization, government or industry. In addition, representatives from national and international agencies and industrial associations are invited as observers.

6. WORKING PROCEDURES

Approximately one year in advance of a meeting of a working group, the agents to be evaluated are announced and participants are selected by IARC staff in consultation with other experts. Subsequently, relevant biological and epidemiological data are collected by IARC from recognized sources of information on carcinogenesis, including data storage and retrieval systems such as CANCERLINE, MEDLINE and TOXLINE. Bibliographical sources for data on genetic and related effects and on teratogenicity are the Environmental Mutagen Information Center and the Environmental Teratology Information Center, both located at the Oak Ridge National Laboratory, USA.

The major collection of data and the preparation of first drafts of the sections on chemical and physical properties, on production and use, on occurrence, and on analysis are carried out under a separate contract funded by the US National Cancer Institute. Efforts are made to supplement this information with data from other national and international sources. Representatives from industrial associations may assist in the preparation of sections on production and use.

Production and trade data are obtained from governmental and trade publications and, in some cases, by direct contact with industries. Separate production data on some agents may not be available because their publication could disclose confidential information.

Information on uses is usually obtained from published sources but is often complemented by direct contact with manufacturers.

Six months before the meeting, reference material is sent to experts, or is used by IARC staff, to prepare sections for the first drafts of monographs. The complete first drafts are compiled by IARC staff and sent, prior to the meeting, to all participants of the Working Group for review.

The Working Group meets in Lyon for seven to eight days to discuss and finalize the texts of the monographs and to formulate the evaluations. After the meeting, the master copy of each monograph is verified by consulting the original literature, edited and prepared for publication. The aim is to publish monographs within nine months of the Working Group meeting.

7. EXPOSURE DATA

Sections that indicate the extent of past and present human exposure, the sources of exposure, the persons most likely to be exposed and the factors that contribute to exposure to the agent under study are included at the beginning of each monograph.

Most monographs on individual chemicals or complex mixtures include sections on chemical and physical data, and production, use, occurrence and analysis. In other monographs, for example on physical agents, biological factors, occupational exposures and cultural habits, other sections may be included, such as: historical perspectives, description of an industry or habit, exposures in the workplace or chemistry of the complex mixture.

The Chemical Abstracts Services Registry Number, the latest Chemical Abstracts Primary Name and the IUPAC Systematic Name are recorded. Other synonyms and trade names are given, but the list is not necessarily comprehensive. Some of the trade names may be those of mixtures in which the agent being evaluated is only one of the ingredients.

Information on chemical and physical properties and, in particular, data relevant to identification, occurrence and biological activity are included. A separate description of technical products gives relevant specifications and includes available information on composition and impurities.

The dates of first synthesis and of first commercial production of an agent are provided; for agents which do not occur naturally, this information may allow a reasonable estimate to be made of the date before which no human exposure to the agent could have occurred. The dates of first reported occurrence of an exposure are also provided. In addition, methods of synthesis used in past and present commercial production and different methods of production which may give rise to different impurities are described.

Data on production, foreign trade and uses are obtained for representative regions, which usually include Europe, Japan and the USA. It should not, however, be inferred that those areas or nations are necessarily the sole or major sources or users of the agent being evaluated.

Some identified uses may not be current or major applications, and the coverage is not necessarily comprehensive. In the case of drugs, mention of their therapeutic uses does not necessarily represent current practice nor does it imply judgement as to their clinical efficacy.

Information on the occurrence of an agent in the environment is obtained from data derived from the monitoring and surveillance of levels in occupational environments, air, water, soil, foods and animal and human tissues. When available, data on the generation, persistence and bioaccumulation of the agent are also included.

Statements concerning regulations and guidelines (e.g., pesticide registrations, maximal levels permitted in foods, occupational exposure limits) are included for some countries as indications of potential exposures, but they may not reflect the most recent situation, since such limits are continuously reviewed and modified. The absence of information on regulatory status for a country should not be taken to imply that that country does not have regulations with regard to the agent.

The purpose of the section on analysis is to give the reader an overview of current methods cited in the literature, with emphasis on those widely used for regulatory purposes. No critical evaluation or recommendation of any of the methods is meant or implied. Methods for monitoring human exposure are also given, when available. The IARC publishes a series of volumes, *Environmental Carcinogens: Selected Methods of Analysis*(9), that describe validated methods for analysing a wide variety of agents.

8. BIOLOGICAL DATA RELEVANT TO THE EVALUATION OF CARCINOGENICITY TO HUMANS

The term 'carcinogen' is used in these monographs to denote an agent that is capable of increasing the incidence of malignant neoplasms; the induction of benign neoplasms may in some circumstances (see p. 23) contribute to the judgement that an agent is carcinogenic. The terms 'neoplasm' and 'tumour' are used interchangeably.

Some epidemiological and experimental studies indicate that different agents may act at different stages in the carcinogenic process, probably by fundamentally different mechanisms. In the present state of knowledge, the aim of the *Monographs* is to evaluate evidence of carcinogenicity at any stage in the carcinogenic process independently of the underlying mechanism involved. There is as yet insufficient information to implement a classification of agents according to their mechanism of action(5).

Definitive evidence of carcinogenicity in humans is provided by epidemiological studies. Evidence relevant to human carcinogenicity may also be provided by experimental studies of carcinogenicity in animals and by other biological data, particularly those relating to humans.

The available studies are summarized by the working groups, with particular regard to the qualitative aspects discussed below. In general, numerical findings are indicated as they appear in the original report; units are converted when necessary for easier comparison. The Working Group may conduct additional analyses of the published data and use them in

their assessment of the evidence and may include them in their summary of a study; the results of such supplementary analyses are given in square brackets. Any comments are also made in square brackets; however, these are kept to a minimum, being restricted to those instances in which it is felt that an important aspect of a study, directly impinging on its interpretation, should be brought to the attention of the reader.

9. EVIDENCE FOR CARCINOGENICITY IN EXPERIMENTAL ANIMALS

For several agents (e.g., 4-aminobiphenyl, bis(chloromethyl)ether, diethylstilboestrol, melphalan, 8-methoxypsoralen(methoxsalen) plus UVR, mustard gas and vinyl chloride), evidence of carcinogenicity in experimental animals preceded evidence obtained from epidemiological studies or case reports. Information compiled from the first 41 volumes of the *IARC Monographs*(10) shows that, of the 44 agents for which there is *sufficient* or *limited evidence* of carcinogenicity to humans (see p. 30), all 37 that have been tested adequately experimentally produce cancer in at least one animal species. Although this association cannot establish that all agents that cause cancer in experimental animals also cause cancer in humans, nevertheless, **in the absence of adequate data on humans, it is biologically plausible and prudent to regard agents for which there is *sufficient evidence* (see p. 30) of carcinogenicity in experimental animals as if they presented a carcinogenic risk to humans.**

The monographs are not intended to summarize all published studies. Those that are inadequate (e.g., too short a duration, too few animals, poor survival; see below) or are judged irrelevant to the evaluation are generally omitted. They may be mentioned briefly, particularly when the information is considered to be a useful supplement to that of other reports or when they provide the only data available. Their inclusion does not, however, imply acceptance of the adequacy of the experimental design or of the analysis and interpretation of their results. Guidelines for adequate long-term carcinogenicity experiments have been outlined(e.g., 11).

The nature and extent of impurities or contaminants present in the agent being evaluated are given when available. Mention is made of all routes of exposure by which the agent has been adequately studied and of all species in which relevant experiments have been performed. Animal strain, sex, numbers per group, age at start of treatment and survival are reported.

Experiments in which the agent was administered in conjunction with known carcinogens or factors that modify carcinogenic effects are also reported. Experiments on the carcinogenicity of known metabolites and derivatives may be included.

(a) *Qualitative aspects*

The overall assessment of the carcinogenicity of an agent involves several considerations of qualitative importance, including (i) the experimental conditions under which the test was performed, including route and schedule of exposure, species, strain, sex, age, duration of follow-up; (ii) the consistency with which the agent has been shown to be carcinogenic, e.g., in how many species and at which target organs(s); (iii) the spectrum of neoplastic

response, from benign tumours to malignant neoplasms; and (iv) the possible role of modifying factors.

Considerations of importance to the Working Group in the interpretation and evaluation of a particular study include: (i) how clearly the agent was defined; (ii) whether the dose was adequately monitored, particularly in inhalation experiments; (iii) whether the doses used were appropriate and whether the survival of treated animals was similar to that of controls; (iv) whether there were adequate numbers of animals per group; (v) whether animals of both sexes were used; (vi) whether animals were allocated randomly to groups; (vii) whether the duration of observation was adequate; and (viii) whether the data were adequately reported. If available, recent data on the incidence of specific tumours in historical controls, as well as in concurrent controls, should be taken into account in the evaluation of tumour response.

When benign tumours occur together with and originate from the same cell type in an organ or tissue as malignant tumours in a particular study and appear to represent a stage in the progression to malignancy, it may be valid to combine them in assessing tumour incidence. The occurrence of lesions presumed to be preneoplastic may in certain instances aid in assessing the biological plausibility of any neoplastic response observed.

Among the many agents that have been studied extensively, there are few instances in which the only neoplasms induced were benign. Benign tumours in experimental animals frequently represent a stage in the evolution of a malignant neoplasm, but they may be 'endpoints' that do not readily undergo transition to malignancy. However, if an agent is found to induce only benign neoplasms, it should be suspected of being a carcinogen and it requires further investigation.

(b) Quantitative aspects

The probability that tumours will occur may depend on the species and strain, the dose of the carcinogen and the route and period of exposure. Evidence of an increased incidence of neoplasms with increased exposure strengthens the inference of a causal association between exposure to the agent and the development of neoplasms.

The form of the dose-response relationship can vary widely, depending on the particular agent under study and the target organ. Since many chemicals require metabolic activation before being converted into their reactive intermediates, both metabolic and pharmacokinetic aspects are important in determining the dose-response pattern. Saturation of steps such as absorption, activation, inactivation and elimination of the carcinogen may produce nonlinearity in the dose-response relationship, as could saturation of processes such as DNA repair(12,13).

(c) Statistical analysis of long-term experiments in animals

Factors considered by the Working Group include the adequacy of the information given for each treatment group: (i) the number of animals on study and the number examined histologically, (ii) the number of animals with a given tumour type and (iii) length of survival. The statistical methods used should be clearly stated and should be the generally accepted techniques refined for this purpose(13,14). When there is no difference in survival

between control and treatment groups, the Working Group usually compares the proportions of animals developing each tumour type in each of the groups. Otherwise, consideration is given as to whether or not appropriate adjustments have been made for differences in survival. These adjustments can include: comparisons of the proportions of tumour-bearing animals among the 'effective number' of animals alive at the time the first tumour is discovered, in the case where most differences in survival occur before tumours appear; life-table methods, when tumours are visible or when they may be considered 'fatal' because mortality rapidly follows tumour development; and the Mantel-Haenszel test or logistic regression, when occult tumours do not affect the animals' risk of dying but are 'incidental' findings at autopsy.

In practice, classifying tumours as fatal or incidental may be difficult. Several survival-adjusted methods have been developed that do not require this distinction(13), although they have not been fully evaluated.

10. OTHER RELEVANT DATA IN EXPERIMENTAL SYSTEMS AND HUMANS

(a) *Structure-activity considerations*

This section describes structure-activity correlations that are relevant to an evaluation of the carcinogenicity of an agent.

(b) *Absorption, distribution, excretion and metabolism*

Concise information is given on absorption, distribution (including placental transfer) and excretion. Kinetic factors that may affect the dose-reponse relationship, such as saturation of uptake, protein binding, metabolic activation, detoxification and DNA-repair processes, are mentioned. Studies that indicate the metabolic fate of the agent in experimental animals and humans are summarized briefly, and comparisons of data from animals and humans are made when possible. Comparative information on the relationship between exposure and the dose that reaches the target site may be of particular importance for extrapolation between species.

(c) *Toxicity*

Data are given on acute and chronic toxic effects (other than cancer), such as organ toxicity, immunotoxicity, endocrine effects and preneoplastic lesions. Effects on reproduction, teratogenicity, fetotoxicity and embryotoxicity are also summarized briefly.

(d) *Genetic and related effects*

Tests of genetic and related effects may indicate possible carcinogenic activity. They can also be used in detecting active metabolites of known carcinogens in human or animal body fluids, in detecting active components in complex mixtures and in the elucidation of possible mechanisms of carcinogenesis.

The available data are interpreted critically by phylogenetic group according to the endpoints detected, which may include DNA damage, gene mutation, sister chromatid exchange, micronuclei, chromosomal aberrations, aneuploidy and cell transformation. The

concentrations (doses) employed are given and mention is made of whether an exogenous metabolic system was required. When appropriate, these data may be represented by bar graphs (activity profiles), with corresponding summary tables and listings of test systems, data and references. Detailed information on the preparation of these profiles is given in an appendix to those volumes in which they are used.

Positive results in tests using prokaryotes, lower eukaryotes, plants, insects and cultured mammalian cells suggest that genetic and related effects (and therefore possibly carcinogenic effects) could occur in mammals. Results from such tests may also give information about the types of genetic effects produced by an agent and about the involvement of metabolic activation. Some endpoints described are clearly genetic in nature (e.g., gene mutations and chromosomal aberrations), others are to a greater or lesser degree associated with genetic effects (e.g., unscheduled DNA synthesis). In-vitro tests for tumour-promoting activity and for cell transformation may detect changes that are not necessarily the result of genetic alterations but that may have specific relevance to the process of carcinogenesis. A critical appraisal of these tests has been published(11).

Genetic or other activity detected in the systems mentioned above is not always manifest in whole mammals. Positive indications of genetic effects in experimental mammals and in humans are regarded as being of greater relevance than those in other organisms. The demonstration that an agent can induce gene and chromosomal mutations in whole mammals indicates that it may have the potential for carcinogenic activity, although this activity may not be detectably expressed in any or all species tested. The relative potency of agents in tests for mutagenicity and related effects is not a reliable indicator of carcinogenic potency. Negative results in tests for mutagenicity in selected tissues from animals treated *in vivo* provide less weight, partly because they do not exclude the possibility of an effect in tissues other than those examined. Moreover, negative results in short-term tests with genetic endpoints cannot be considered to provide evidence to rule out carcinogenicity of agents that act through other mechanisms. Factors may arise in many tests that could give misleading results; these have been discussed in detail elsewhere(11).

The adequacy of epidemiological studies of reproductive outcomes and genetic and related effects in humans is evaluated by the same criteria as are applied to epidemiological studies of cancer.

11. EVIDENCE FOR CARCINOGENICITY IN HUMANS

(a) Types of studies considered

Three types of epidemiological studies of cancer contribute data to the assessment of carcinogenicity in humans — cohort studies, case-control studies and correlation studies. Rarely, results from randomized trials may be available. Case reports of cancer in humans exposed to particular agents are also reviewed.

Cohort and case-control studies relate individual exposure to the agent under study to the occurrence of cancer in individuals, and provide an estimate of relative risk (ratio of

incidence in those exposed to incidence in those not exposed) as the main measure of association.

In correlation studies, the units of investigation are usually whole populations (e.g., in particular geographical areas or at particular times), and cancer incidence is related to a summary measure of the exposure of the population to the agent under study. Because individual exposure is not documented, however, a causal relationship is less easy to infer from correlation studies than from cohort and case-control studies.

Case reports generally arise from a suspicion, based on clinical experience, that the concurrence of two events — that is, exposure to a particular agent and occurrence of a cancer — has happened rather more frequently than would be expected by chance. Case reports usually lack complete ascertainment of cases in any population, definition or enumeration of the population at risk and estimation of the expected number of cases in the absence of exposure.

The uncertainties surrounding interpretation of case reports and correlation studies make them inadequate, except in rare instances, to form the sole basis for inferring a causal relationship. When taken together with case-control and cohort studies, however, relevant case reports or correlation studies may add materially to the judgement that a causal relationship is present.

Epidemiological studies of benign neoplasms and presumed preneoplastic lesions are also reviewed by working groups. They may, in some instances, strengthen inferences drawn from studies of cancer itself.

(b) Quality of studies considered

It is necessary to take into account the possible roles of bias, confounding and chance in the interpretation of epidemiological studies. By 'bias' is meant the operation of factors in study design or execution that lead erroneously to a stronger or weaker association between an agent and disease than in fact exists. By 'confounding' is meant a situation in which the relationship between an agent and a disease is made to appear stronger or to appear weaker than it truly is as a result of an association between the agent and another agent that is associated with either an increase or decrease in the incidence of the disease. In evaluating the extent to which these factors have been minimized in an individual study, working groups consider a number of aspects of design and analysis as described in the report of the study. Most of these considerations apply equally to case-control, cohort and correlation studies. Lack of clarity of any of these aspects in the reporting of a study can decrease its credibility and its consequent weighting in the final evaluation of the exposure.

Firstly, the study population, disease (or diseases) and exposure should have been well defined by the authors. Cases in the study population should have been identified in a way that was independent of the exposure of interest, and exposure should have been assessed in a way that was not related to disease status.

Secondly, the authors should have taken account in the study design and analysis of other variables that can influence the risk of disease and may have been related to the exposure of interest. Potential confounding by such variables should have been dealt with

either in the design of the study, such as by matching, or in the analysis, by statistical adjustment. In cohort studies, comparisons with local rates of disease may be more appropriate than those with national rates. Internal comparisons of disease frequency among individuals at different levels of exposure should also have been made in the study.

Thirdly, the authors should have reported the basic data on which the conclusions are founded, even if sophisticated statistical analyses were employed. At the very least, they should have given the numbers of exposed and unexposed cases and controls in a case-control study and the numbers of cases observed and expected in a cohort study. Further tabulations by time since exposure began and other temporal factors are also important. In a cohort study, data on all cancer sites and all causes of death should have been given, to avoid the possibility of reporting bias. In a case-control study, the effects of investigated factors other than the agent of interest should have been reported.

Finally, the statistical methods used to obtain estimates of relative risk, absolute cancer rates, confidence intervals and significance tests, and to adjust for confounding should have been clearly stated by the authors. The methods used should preferably have been the generally accepted techniques that have been refined since the mid-1970s. These methods have been reviewed for case-control studies(15) and for cohort studies(16).

(c) *Quantitative considerations*

Detailed analyses of both relative and absolute risks in relation to age at first exposure and to temporal variables, such as time since first exposure, duration of exposure and time since exposure ceased, are reviewed and summarized when available. The analysis of temporal relationships can provide a useful guide in formulating models of carcinogenesis. In particular, such analyses may suggest whether a carcinogen acts early or late in the process of carcinogenesis(5), although such speculative inferences cannot be used to draw firm conclusions concerning the mechanism of action of the agent and hence the shape (linear or otherwise) of the dose-response relationship below the range of observation.

(d) *Criteria for causality*

After the quality of individual epidemiological studies has been summarized and assessed, a judgement is made concerning the strength of evidence that the agent in question is carcinogenic for humans. In making their judgement, the Working Group considers several criteria for causality. A strong association (i.e., a large relative risk) is more likely to indicate causality than a weak association, although it is recognized that relative risks of small magnitude do not imply lack of causality and may be important if the disease is common. Associations that are replicated in several studies of the same design or using different epidemiological approaches or under different circumstances of exposure are more likely to represent a causal relationship than isolated observations from single studies. If there are inconsistent results among investigations, possible reasons are sought (such as differences in amount of exposure), and results of studies judged to be of high quality are given more weight than those from studies judged to be methodologically less sound. When suspicion of carcinogenicity arises largely from a single study, these data are not combined with those from later studies in any subsequent reassessment of the strength of the evidence.

If the risk of the disease in question increases with the amount of exposure, this is considered to be a strong indication of causality, although absence of a graded response is not necessarily evidence against a causal relationship. Demonstration of a decline in risk after cessation of or reduction in exposure in individuals or in whole populations also supports a causal interpretation of the findings.

Although the same carcinogenic agent may act upon more than one target, the specificity of an association (i.e., an increased occurrence of cancer at one anatomical site or of one morphological type) adds plausibility to a causal relationship, particularly when excess cancer occurrence is limited to one morphological type within the same organ.

Although rarely available, results from randomized trials showing different rates among exposed and unexposed individuals provide particularly strong evidence for causality.

When several epidemiological studies show little or no indication of an association between an agent and cancer, the judgement may be made that, in the aggregate, they show evidence of lack of carcinogenicity. Such a judgement requires first of all that the studies giving rise to it meet, to a sufficient degree, the standards of design and analysis described above. Specifically, the possibility that bias, confounding or misclassification of exposure or outcome could explain the observed results should be considered and excluded with reasonable certainty. In addition, all studies that are judged to be methodologically sound should be consistent with a relative risk of unity for any observed level of exposure to the agent and, when considered together, should provide a pooled estimate of relative risk which is at or near unity and has a narrow confidence interval, due to sufficient population size. Moreover, no individual study nor the pooled results of all the studies should show any consistent tendency for relative risk of cancer to increase with increasing amount of exposure to the agent. It is important to note that evidence of lack of carcinogenicity obtained in this way from several epidemiological studies can apply only to the type(s) of cancer studied and to dose levels of the agent and intervals between first exposure to it and observation of disease that are the same as or less than those observed in all the studies. Experience with human cancer indicates that, for some agents, the period from first exposure to the development of clinical cancer is seldom less than 20 years; latent periods substantially shorter than 30 years cannot provide evidence for lack of carcinogenicity.

12. SUMMARY OF DATA REPORTED

In this section, the relevant experimental and epidemiological data are summarized. Only reports, other than in abstract form, that meet the criteria outlined on pp. 18-19 are considered for evaluating carcinogenicity. Inadequate studies are generally not summarized: such studies are usually identified by a square-bracketed comment in the text.

(a) Exposures

Human exposure is summarized on the basis of elements such as production, use, occurrence in the environment and determinations in human tissues and body fluids. Quantitative data are given when available.

(b) *Experimental carcinogenicity data*

Data relevant to the evaluation of the carcinogenicity of the agent in animals are summarized. For each animal species and route of administration, it is stated whether an increased incidence of neoplasms was observed, and the tumour sites are indicated. If the agent produced tumours after prenatal exposure or in single-dose experiments, this is also indicated. Dose-response and other quantitative data may be given when available. Negative findings are also summarized.

(c) *Human carcinogenicity data*

Results of epidemiological studies that are considered to be pertinent to an assessment of human carcinogenicity are summarized. When relevant, case reports and correlation studies are also considered.

(d) *Other relevant data*

Structure-activity correlations are mentioned when relevant.

Toxicological information and data on kinetics and metabolism in experimental animals are given when considered relevant. The results of tests for genetic and related effects are summarized for whole mammals, cultured mammalian cells and nonmammalian systems.

Data on other biological effects in humans of particular relevance are summarized. These may include kinetic and metabolic considerations and evidence of DNA binding, persistence of DNA lesions or genetic damage in humans exposed to the agent.

When available, comparisons of such data for humans and for animals, and particularly animals that have developed cancer, are described.

13. EVALUATION

Evaluations of the strength of the evidence for carcinogenicity arising from human and experimental animal data are made, using standard terms.

It is recognized that the criteria for these evaluations, described below, cannot encompass all of the factors that may be relevant to an evaluation of the carcinogenicity of an agent. In considering all of the relevant data, the Working Group may assign the agent to a higher or lower category than a strict interpretation of these criteria would indicate.

(a) *Degrees of evidence for carcinogenicity to humans and to experimental animals and supporting evidence*

It should be noted that these categories refer only to the strength of the evidence that these agents are carcinogenic and not to the extent of their carcinogenic activity (potency) nor to the mechanism involved. The classification of some agents may change as new information becomes available.

(i) *Human carcinogenicity data*

The evidence relevant to carcinogenicity from studies in humans is classified into one of the following categories:

Sufficient evidence of carcinogenicity: The Working Group considers that a causal relationship has been established between exposure to the agent and human cancer. That is, a positive relationship has been observed between exposure to the agent and cancer in studies in which chance, bias and confounding could be ruled out with reasonable confidence.

Limited evidence of carcinogenicity: A positive association has been observed between exposure to the agent and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or confounding could not be ruled out with reasonable confidence.

Inadequate evidence of carcinogenicity: The available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding the presence or absence of a causal association.

Evidence suggesting lack of carcinogenicity: There are several adequate studies covering the full range of doses to which human beings are known to be exposed, which are mutually consistent in not showing a positive association between exposure to the agent and any studied cancer at any observed level of exposure. A conclusion of 'evidence suggesting lack of carcinogenicity' is inevitably limited to the cancer sites, circumstances and doses of exposure and length of observation covered by the available studies. In addition, the possibility of a very small risk at the levels of exposure studied can never be excluded.

In some instances, the above categories may be used to classify the degree of evidence for the carcinogenicity of the agent for specific organs or tissues.

(ii) *Experimental carcinogenicity data*

The evidence relevant to carcinogenicity in experimental animals is classified into one of the following categories:

Sufficient evidence of carcinogenicity: The Working Group considers that a causal relationship has been established between the agent and an increased incidence of malignant neoplasms or of an appropriate combination of benign and malignant neoplasms (as described on p.23) in (a) two or more species of animals or (b) in two or more independent studies in one species carried out at different times or in different laboratories or under different protocols.

Exceptionally, a single study in one species might be considered to provide sufficient evidence of carcinogenicity when malignant neoplasms occur to an unusual degree with regard to incidence, site, type of tumour or age at onset.

In the absence of adequate data on humans, it is biologically plausible and prudent to regard agents for which there is *sufficient evidence* of carcinogenicity in experimental animals as if they presented a carcinogenic risk to humans.

Limited evidence of carcinogenicity: The data suggest a carcinogenic effect but are limited for making a definitive evaluation because, e.g., (a) the evidence of carcinogenicity is restricted to a single experiment; or (b) there are unresolved questions regarding the adequacy of the design, conduct or interpretation of the study; or (c) the agent increases the incidence only of benign neoplasms or lesions of uncertain neoplastic potential, or of certain neoplasms which may occur spontaneously in high incidences in certain strains.

Inadequate evidence of carcinogenicity: The studies cannot be interpreted as showing either the presence or absence of a carcinogenic effect because of major qualitative or quantitative limitations.

Evidence suggesting lack of carcinogenicity: Adequate studies involving at least two species are available which show that, within the limits of the tests used, the agent is not carcinogenic. A conclusion of evidence suggesting lack of carcinogenicity is inevitably limited to the species, tumour sites and doses of exposure studied.

(iii) *Supporting evidence of carcinogenicity*

The other relevant data judged to be of sufficient importance as to affect the making of the overall evaluation are indicated.

(b) *Overall evaluation*

Finally, the total body of evidence is taken into account; the agent is described according to the wording of one of the following categories, and the designated group is given. The categorization of an agent is a matter of scientific judgement, reflecting the strength of the evidence derived from studies in humans and in experimental animals and from other relevant data.

Group 1 — The agent is carcinogenic to humans.

This category is used only when there is *sufficient evidence* of carcinogenicity in humans.

Group 2

This category includes agents for which, at one extreme, the degree of evidence of carcinogenicity in humans is almost sufficient, as well as agents for which, at the other extreme, there are no human data but for which there is experimental evidence of carcinogenicity. Agents are assigned to either 2A (probably carcinogenic) or 2B (possibly carcinogenic) on the basis of epidemiological, experimental and other relevant data.

Group 2A — The agent is probably carcinogenic to humans.

This category is used when there is *limited evidence* of carcinogenicity in humans and *sufficient evidence* of carcinogenicity in experimental animals. Exceptionally, an agent may be classified into this category solely on the basis of *limited evidence* of carcinogenicity in humans or of *sufficient evidence* of carcinogenicity in experimental animals strengthened by supporting evidence from other relevant data.

Group 2B — The agent is possibly carcinogenic to humans.

This category is generally used for agents for which there is *limited evidence* in humans in the absence of *sufficient evidence* in experimental animals. It may also be used when there is *inadequate evidence* of carcinogenicity in humans or when human data are nonexistent but there is *sufficient evidence* of carcinogenicity in experimental animals. In some instances, an agent for which there is inadequate evidence or no data in humans but *limited evidence* of carcinogenicity in experimental animals together with supporting evidence from other relevant data may be placed in this group.

Group 3 — The agent is not classifiable as to its carcinogenicity to humans.

Agents are placed in this category when they do not fall into any other group.

Group 4 — The agent is probably not carcinogenic to humans.

This category is used for agents for which there is *evidence suggesting lack of carcinogenicity* in humans together with *evidence suggesting lack of carcinogenicity* in experimental animals. In some circumstances, agents for which there is *inadequate evidence* of or no data on carcinogenicity in humans but *evidence suggesting lack of carcinogenicity* in experimental animals, consistently and strongly supported by a broad range of other relevant data, may be classified in this group.

References

1. IARC (1977) *IARC Monographs Programme on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Preamble* (IARC intern. tech. Rep. No. 77/002), Lyon
2. IARC (1978) *Chemicals with Sufficient Evidence of Carcinogenicity in Experimental Animals — IARC Monographs Volumes 1-17* (IARC intern. tech. Rep. No. 78/003), Lyon
3. IARC (1979) *Criteria to Select Chemicals for IARC Monographs* (IARC intern. tech. Rep. No. 79/003), Lyon
4. IARC (1982) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 4, Chemicals, Industrial Processes and Industries Associated with Cancer in Humans* (IARC Monographs, Volumes 1 to 29), Lyon
5. IARC (1983) *Approaches to Classifying Chemical Carcinogens According to Mechanism of Action* (IARC intern. tech. Rep. No. 83/001), Lyon
6. IARC (1973-1984) *Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity, Numbers 1-12*, Lyon
 - Number 1 (1973) 52 pages
 - Number 2 (1973) 77 pages
 - Number 3 (1974) 67 pages
 - Number 4 (1974) 97 pages
 - Number 5 (1975) 88 pages
 - Number 6 (1976) 360 pages

- Number 7 (1978) 460 pages
Number 8 (1979) 604 pages
Number 9 (1981) 294 pages
Number 10 (1983) 326 pages
Number 11 (1984) 370 pages
Number 12 (1986) 385 pages
7. Muir, C. & Wagner, G., eds (1977-87) *Directory of On-going Studies in Cancer Epidemiology 1977-87 (IARC Scientific Publications)*, Lyon, International Agency for Research on Cancer
 8. IARC (1984) *Chemicals and Exposures to Complex Mixtures Recommended for Evaluation in IARC Monographs and Chemicals and Complex Mixtures Recommended for Long-term Carcinogenicity Testing (IARC intern. tech. Rep. No. 84/002)*, Lyon
 9. *Environmental Carcinogens. Selected Methods of Analysis:*
 - Vol. 1. *Analysis of Volatile Nitrosamines in Food (IARC Scientific Publications No. 18)*. Edited by R. Preussmann, M. Castegnaro, E.A. Walker & A.E. Wassermann (1978)
 - Vol. 2. *Methods for the Measurement of Vinyl Chloride in Poly(vinyl chloride), Air, Water and Foodstuffs (IARC Scientific Publications No. 22)*. Edited by D.C.M. Squirrell & W. Thain (1978)
 - Vol. 3. *Analysis of Polycyclic Aromatic Hydrocarbons in Environmental Samples (IARC Scientific Publications No. 29)*. Edited by M. Castegnaro, P. Bogovski, H. Kunte & E.A. Walker (1979)
 - Vol. 4. *Some Aromatic Amines and Azo Dyes in the General and Industrial Environment (IARC Scientific Publications No. 40)*. Edited by L. Fishbein, M. Castegnaro, I.K. O'Neill & H. Bartsch (1981)
 - Vol. 5. *Some Mycotoxins (IARC Scientific Publications No. 44)*. Edited by L. Stoloff, M. Castegnaro, P. Scott, I.K. O'Neill & H. Bartsch (1982)
 - Vol. 6. *N-Nitroso Compounds (IARC Scientific Publications No. 45)*. Edited by R. Preussmann, I.K. O'Neill, G. Eisenbrand, B. Spiegelhalter & H. Bartsch (1983)
 - Vol. 7. *Some Volatile Halogenated Hydrocarbons (IARC Scientific Publications No. 68)*. Edited by L. Fishbein & I.K. O'Neill (1985)
 - Vol. 8. *Some Metals: As, Be, Cd, Cr, Ni, Pb, Se, Zn (IARC Scientific Publications No. 71)*. Edited by I.K. O'Neill, P. Schuller & L. Fishbein (1986)
 - Vol. 9. *Passive Smoking (IARC Scientific Publications No. 81)*. Edited by I.K. O'Neill, K.D. Brunnemann, B. Dodet & D. Hoffmann (1987)
 10. Wilbourn, J., Haroun, L., Heseltine, E., Kaldor, J., Partensky, C. & Vainio, H. (1986) Response of experimental animals to human carcinogens: an analysis based upon the IARC Monographs Programme. *Carcinogenesis*, 7, 1853-1863
 11. Montesano, R., Bartsch, H., Vainio, H., Wilbourn, J. & Yamasaki, H., eds (1986) *Long-term and Short-term Assays for Carcinogenesis — A Critical Appraisal (IARC Scientific Publications No. 83)*, Lyon, International Agency for Research on Cancer
 12. Hoel, D.G., Kaplan, N.L. & Anderson, M.W. (1983) Implication of nonlinear kinetics on risk estimation in carcinogenesis. *Science*, 219, 1032-1037

13. Gart, J.J., Krewski, D., Lee, P.N., Tarone, R.E. & Wahrendorf, J. (1986) *Statistical Methods in Cancer Research, Vol. 3, The Design and Analysis of Long-term Animal Experiments (IARC Scientific Publications No.79)*, Lyon, International Agency for Research on Cancer
14. Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S. & Wahrendorf, J. (1980) *Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments*. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 2, Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal*, Lyon, pp. 311-426
15. Breslow, N.E. & Day, N.E. (1980) *Statistical Methods in Cancer Research, Vol. 1, The Analysis of Case-control Studies (IARC Scientific Publications No. 32)*, Lyon, International Agency for Research on Cancer
16. Breslow, N.E. & Day, N.E. (1987) *Statistical Methods in Cancer Research, Vol. 2, The Design and Analysis of Cohort Studies (IARC Scientific Publications No. 82)*, Lyon, International Agency for Research on Cancer